🔗 Share this article

As the United States undertakes historic changes to its vaccine recommendations, one figure has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on coronavirus vaccinations during the global health crisis and has concentrated on alleged deaths following COVID-19 immunization in her short position at the FDA.

Planned Changes to Childhood Vaccine Program

Health officials were set to reveal major revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US at odds with much of the global community with insufficient data for benefit. The planned update has been delayed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to run the division this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the drug and vaccine divisions as Høeg and Dr. Prasad consolidate power at the agency – and it suggests a increased emphasis upon rolling back already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending some childhood immunization guidelines in the US so as to align more similar to Denmark, a country with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

To date comments, she has kept her attention on vaccination policy – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Background

The appointee has little discernible experience in pharmaceutical research, regulation or leadership, which has been typical for former heads of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the necessary background” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in managing a large organization. She has no expertise in industry regulation.”

Previous directors of the center would “understand laws and regulations and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who ran CBER have had.”

This division has an vast range of responsibilities at the FDA, Woodcock emphasized.

“Many people just zeroes in on the new drug program, but the generic drug division approves thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and all of those must be supervised,” Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative aspect to the position, which supervises over 5,000 personnel. “It’s a massive leadership role, if you do it right,” Woodcock added.

Agency Reaction and Disputed Programs

Regarding concerns about Dr. Høeg's credentials and whether this appointment represents greater collaboration among agency officials on immunizations, a spokesperson responded that the “questions stem from inaccurate premises”.

“Her experience matches the responsibilities of her job,” the official explained, pointing to the months Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg inherits the agency head's new expedited review system, a disputed one-day drug-approval program that allegedly worried her predecessors. “By what process are these therapies being picked for this expedited pathway? Who is making the choices?” Dr. Howard said. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he said, “the FDA appears to be shifting towards more relaxed oversight of most medications, aside from vaccines.”

Documented History on Immunizations

Regarding immunizations, Høeg has a more documented, if problematic, track record, Howard have noted. She released a research paper using unverified crowd-sourced reports to assess the incidence of myocarditis after COVID-19 vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Included in her “policy goals” for the new administration included changing rules for new vaccines and halting “unnecessary” immunizations, she said post-election on a podcast. At the FDA, Høeg has allegedly proposed barring young men from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who begins with her beliefs and reverse-engineers to accommodate the evidence in a extremely disingenuous, dishonest fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|